Biocon Pharma Inc. 3
3 · Bicara Therapeutics Inc. · Filed Sep 12, 2024
Insider Transaction Report
Form 3
Biocon Ltd
10% Owner
Holdings
- 115,757(indirect: By Biocon Limited)
Common Stock
- (indirect: By Biocon Limited)
Series Seed Redeemable Convertible Preferred Stock
→ Common Stock (4,327,365 underlying) - (indirect: By Biocon Pharma Inc.)
Series Seed Redeemable Convertible Preferred Stock
→ Common Stock (1,080,775 underlying)
Footnotes (3)
- [F1]Shares held by Biocon Limited ("Biocon Ltd"). Kiran Mazumdar-Shaw is the managing member of Biocon Ltd. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F2]Each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") is convertible into Common Stock on a 9.2435-to-one basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Preferred Stock has no expiration date.
- [F3]Shares held by Biocon Pharma Inc. ("Biocon Pharma"). Kiran Mazumdar-Shaw is the managing member of Biocon Pharma. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.